Advertisement

Topics

Gene therapy company Audentes Therapeutics nets $142mm in FOPO

15:40 EDT 12 Oct 2018 | Elsevier Business Intelligence

Audentes Therapeutics Inc. (gene therapy) netted $141.8mm in a follow-on public offering of 5.2mm common shares at $29. The ...

Original Article: Gene therapy company Audentes Therapeutics nets $142mm in FOPO

NEXT ARTICLE

More From BioPortfolio on "Gene therapy company Audentes Therapeutics nets $142mm in FOPO"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...